Answers are grounded in this paper and cite their sources.
Case series reveals therapy-related myeloid neoplasms in ovarian cancer, suggesting a need for awareness and monitoring.
Though Poly (ADP-ribose) polymerase inhibitors (PARPi) are used in ovarian cancer with DNA damage repair pathway and improve survival outcomes, therapy-related myeloid neoplasms (t-MDS/AML) are emerging as a rare but serious complication. Clinico-demographic profile and therapy have been challenging due to paucity of literature, especially from low middle income countries (LMIC).
No takes yet. Share an insight, caveat, or question.
Samantaray et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: